The Rising Tide of the Epidermal Growth Factor Receptor Inhibitor Market
In the age of precision oncology, epidermal growth factor receptor (EGFR) inhibitors have emerged as one of the most promising classes of targeted cancer therapies. EGFR plays a fundamental role in cell growth and proliferation, and its aberrant activation is linked to multiple cancers—most notably non‑small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancers. … Read more